Related by context. Frequent words. (Click for all words.) 68 R sorafenib tablets 65 Meets Primary Endpoint 65 refractory chronic lymphocytic 64 VEGFR2 inhibitor 64 Presents Positive 64 Initiates Phase II 64 Panzem R NCD 63 elotuzumab 63 Vytorin combines 63 Receives Orphan Drug Designation 63 Initiate Phase 62 gastrointestinal mucositis 62 Metastatic Melanoma 62 Enrolls First 61 HGS ETR2 61 developing Zerenex TM 61 FDA Accepts 61 metastatic colorectal 61 Panzem R 61 Belimumab 61 Initiates Phase 61 plus prednisone 61 Completes Enrollment 61 oral deforolimus 60 Inc Therapeutic Competitors 60 Improves Survival 60 Patient Enrollment 60 Inc. Nasdaq IMGN 60 Daclizumab 60 forodesine 60 huC# DM4 60 MKC# 60 HuMax EGFr 60 Commences Phase 60 Pivotal Phase III 60 Darinaparsin 60 Sapacitabine 60 Pivotal Phase 60 Clinical Trial Results 60 ThermoDox R 60 metastatic castration resistant 60 YOUR LOCAL ANIMAL SHELTER 60 liposomal formulation 59 Coadministration 59 Kuvan R 59 Chronic Hepatitis C 59 multi kinase inhibitor 59 Phase III Trial 59 Epratuzumab 59 humanized anti 59 Single Dose 59 phenylketonuria PKU developed 59 R bortezomib 59 Takeda Kyowa Hakko Kirin 59 Dapagliflozin 59 HGS ETR1 59 Renal Cell Carcinoma 59 pulmonology portfolio 58 platinum refractory 58 Pivotal Study 58 Drug Shows Promise 58 Metastatic Colorectal Cancer 58 Phase Ib IIa 58 Study Evaluating 58 recurrent glioblastoma multiforme 58 KRN# 58 relapsed refractory multiple myeloma 58 Onalta 57 investigational mTOR inhibitor 57 Pivotal Trial 57 Entereg R 57 BioGlue R 57 Phase III Clinical Trial 57 ferric citrate 57 APPRAISE 57 Potassium Chloride Sodium Ascorbate 57 advanced carcinoid 57 Inc. NASDAQ QLTI 57 Fibrillex TM 57 GVAX R 57 plus gemcitabine 57 J Am Acad 57 Phase Ib clinical trials 57 HCV protease inhibitor 57 Chronic Lymphocytic Leukemia 56 Phase Ib II 56 dem Ziel der europaweiten 56 SUCCEED trial 56 ongoing Phase 1b 56 tumor lysis syndrome 56 Advancing Drugs 56 dose escalation clinical 56 refractory multiple myeloma 56 phase IIb clinical 56 INVESTING IN SECURITIES INVOLVES 56 cutaneous T 56 Relapsed 56 pseudobulbar affect PBA 56 gets USFDA nod 56 ZALBIN 56 unresectable locally advanced